-Reuters
This Analyst Says Arbutus’ EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ:ABUS) after data…